Sensei Bio is a clinical-stage oncology company developing a novel, personalized cancer vaccine platform based on bacteriophages, small viruses that typically infect bacteria. Sensei’s unique technology allows them to generate bespoke versions of an inactivated bacteriophage decorated with patient-specific neoantigens to stimulate an immune response against tumors.  This platform has the potential to overcome some of the key clinical barriers to therapeutically effective cancer vaccines, including insufficient T cell activation. Sensei will apply its bacteriophage technology to a wide range of cancers starting with prostate, head and neck, and hematologic indications.

No items found.